141 related articles for article (PubMed ID: 35144331)
1. Drug Repositioning Using Temporal Trajectories of Accompanying Comorbidities in Diabetes Mellitus.
Park N; Jeon JY; Jeong E; Kim S; Yoon D
Endocrinol Metab (Seoul); 2022 Feb; 37(1):65-73. PubMed ID: 35144331
[TBL] [Abstract][Full Text] [Related]
2. Comorbidity network for chronic disease: A novel approach to understand type 2 diabetes progression.
Khan A; Uddin S; Srinivasan U
Int J Med Inform; 2018 Jul; 115():1-9. PubMed ID: 29779710
[TBL] [Abstract][Full Text] [Related]
3. A novel individualized drug repositioning approach for predicting personalized candidate drugs for type 1 diabetes mellitus.
Zheng H
Stat Appl Genet Mol Biol; 2019 Jul; 18(5):. PubMed ID: 31287801
[TBL] [Abstract][Full Text] [Related]
4. Drug repositioning for diabetes based on 'omics' data mining.
Zhang M; Luo H; Xi Z; Rogaeva E
PLoS One; 2015; 10(5):e0126082. PubMed ID: 25946000
[TBL] [Abstract][Full Text] [Related]
5. Pleiotropic effects of anti-diabetic drugs: A comprehensive review.
Nath M; Bhattacharjee K; Choudhury Y
Eur J Pharmacol; 2020 Oct; 884():173349. PubMed ID: 32650008
[TBL] [Abstract][Full Text] [Related]
6. DMAP: a connectivity map database to enable identification of novel drug repositioning candidates.
Huang H; Nguyen T; Ibrahim S; Shantharam S; Yue Z; Chen JY
BMC Bioinformatics; 2015; 16 Suppl 13(Suppl 13):S4. PubMed ID: 26423722
[TBL] [Abstract][Full Text] [Related]
7. Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality.
Xu H; Aldrich MC; Chen Q; Liu H; Peterson NB; Dai Q; Levy M; Shah A; Han X; Ruan X; Jiang M; Li Y; Julien JS; Warner J; Friedman C; Roden DM; Denny JC
J Am Med Inform Assoc; 2015 Jan; 22(1):179-91. PubMed ID: 25053577
[TBL] [Abstract][Full Text] [Related]
8. A Study on Methodologies of Drug Repositioning Using Biomedical Big Data: A Focus on Diabetes Mellitus.
Lee S; Jeon S; Kim HS
Endocrinol Metab (Seoul); 2022 Apr; 37(2):195-207. PubMed ID: 35413782
[TBL] [Abstract][Full Text] [Related]
9. Drug Repositioning to Accelerate Drug Development Using Social Media Data: Computational Study on Parkinson Disease.
Zhao M; Yang CC
J Med Internet Res; 2018 Oct; 20(10):e271. PubMed ID: 30309833
[TBL] [Abstract][Full Text] [Related]
10. Temporal trajectories of accompanying comorbidities in patients with type 2 diabetes: a Korean nationwide observational study.
Jeong E; Park N; Kim Y; Jeon JY; Chung WY; Yoon D
Sci Rep; 2020 Mar; 10(1):5535. PubMed ID: 32218498
[TBL] [Abstract][Full Text] [Related]
11. Association between comorbidities and dementia in diabetes mellitus patients: population-based retrospective cohort study.
Kuo SC; Lai SW; Hung HC; Muo CH; Hung SC; Liu LL; Chang CW; Hwu YJ; Chen SL; Sung FC
J Diabetes Complications; 2015; 29(8):1071-6. PubMed ID: 26233574
[TBL] [Abstract][Full Text] [Related]
12. A Systematic Framework for Drug Repositioning from Integrated Omics and Drug Phenotype Profiles Using Pathway-Drug Network.
Jadamba E; Shin M
Biomed Res Int; 2016; 2016():7147039. PubMed ID: 28127549
[TBL] [Abstract][Full Text] [Related]
13. Inferring new drug indications using the complementarity between clinical disease signatures and drug effects.
Jang D; Lee S; Lee J; Kim K; Lee D
J Biomed Inform; 2016 Feb; 59():248-57. PubMed ID: 26707452
[TBL] [Abstract][Full Text] [Related]
14. Infection, antibiotic therapy and risk of colorectal cancer: a nationwide nested case-control study in patients with Type 2 diabetes mellitus.
Wang JL; Chang CH; Lin JW; Wu LC; Chuang LM; Lai MS
Int J Cancer; 2014 Aug; 135(4):956-67. PubMed ID: 24470385
[TBL] [Abstract][Full Text] [Related]
15. Repositioning of Drugs in Cardiometabolic Disorders: Importance and Current Scenario.
Katare PB; Banerjee SK
Curr Top Med Chem; 2016; 16(19):2189-200. PubMed ID: 26881721
[TBL] [Abstract][Full Text] [Related]
16. An integrative approach using real-world data to identify alternative therapeutic uses of existing drugs.
Hosomi K; Fujimoto M; Ushio K; Mao L; Kato J; Takada M
PLoS One; 2018; 13(10):e0204648. PubMed ID: 30300381
[TBL] [Abstract][Full Text] [Related]
17. A two-tiered unsupervised clustering approach for drug repositioning through heterogeneous data integration.
Hameed PN; Verspoor K; Kusljic S; Halgamuge S
BMC Bioinformatics; 2018 Apr; 19(1):129. PubMed ID: 29642848
[TBL] [Abstract][Full Text] [Related]
18. An Integrated System Biology Approach Yields Drug Repositioning Candidates for the Treatment of Heart Failure.
Yang G; Ma A; Qin ZS
Front Genet; 2019; 10():916. PubMed ID: 31608126
[TBL] [Abstract][Full Text] [Related]
19. Management of type 2 diabetes mellitus in children and adolescents.
Springer SC; Silverstein J; Copeland K; Moore KR; Prazar GE; Raymer T; Shiffman RN; Thaker VV; Anderson M; Spann SJ; Flinn SK;
Pediatrics; 2013 Feb; 131(2):e648-64. PubMed ID: 23359584
[TBL] [Abstract][Full Text] [Related]
20. A phenome-guided drug repositioning through a latent variable model.
Bisgin H; Liu Z; Fang H; Kelly R; Xu X; Tong W
BMC Bioinformatics; 2014 Aug; 15(1):267. PubMed ID: 25103881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
